IL2 and COVID-19: In our COVID-19 cohort, we observed increased levels of IL-2, IL-4, IL-15, IL17, and IP-10, which likely activate both T-helper-1 (Th1) and T-helper-2 (Th2) cells and lead to lung inflammation and damage, similar to what has been reported in SARS-CoV and MERS-CoV infections.